CentoLCV™ – The New Standard for Detecting Chromosomal Imbalances
Join our webinar on January 27th discussing CentoLCV™, our comprehensive Large Copy number Variation (CNV) analysis, and why it is the new standard for establishing more accurate molecular diagnoses compared to conventional tests using microarrays.
Prof. Peter Bauer, MD, will be speaking about the importance of copy number variation analysis in shortening the diagnostic odyssey and outlining the implementation of our latest detection platform that combines state-of-the-art genome sequencing technology and our extensive medical expertise. Throughout the webinar, he will provide examples of successful clinical cases ─ leading to better, more informed outcomes for patients suffering from recurrent genomic disorders and complex cases.
Questions and discussion are more than welcome throughout the webinar.
- Copy-number variation analysis as the status quo
- Using shallow whole genome sequencing to perform copy number variation analysis
- How CentoLCV™ performs in a clinical environment
- Successful application of CentoLCV™ in clinical cases
Date & Time
Monday, January 27, 2020 @15.00 CET
See when the event takes place in your time zone.
Unable to attend the webinar? By registering, you will receive a recording of the webinar even if you are unable to attend. If you encounter any problems, please contact us at webinars(at)centogene(dot)com.
Dr. Peter Bauer, Chief Genomic Officer
Prof. Peter Bauer, MD, serves as CENTOGENE’s Chief Genomic Officer, where he combines clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific development, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing.
Prof. Bauer received his board certification in Human Genetics in 2006 and headed the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in neurogenetics, oncogenetics, cardiogenetics, and sequencing technology.